Biotechnology News and Research

RSS

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

NCKU research team identifies Au nanorod complex for cancer therapy

A National Cheng Kung University (NCKU) research team has discovered Near-Infrared Light-Responsive oligonucleotide-gated Au nanoensembles (Au nanorod complex), a potent new anti-cancer complex that is seen as a promising targeted therapy for curing cancer.

24 Aug 2012

Proteonomix enters license agreement for new anti-tumor technology

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an exclusive worldwide license agreement for a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.

23 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

NIH awards $100,000 STTR Phase I Grant to Transgenomic for pancreatic cancer research

Transgenomic, Inc. today announced it has been awarded a $100,000 Small Business Technology Transfer Program (STTR) Phase I Grant by the National Institutes of Health's National Center For Advancing Translational Sciences.

23 Aug 2012

SSEA4+ marker helps identify and isolate precursors of insulin-producing pancreatic cells

For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.

22 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

Massachusetts Institute of Technology to honor IHME's health measurement expert

For the first time, a prestigious technical innovation honor from the Massachusetts Institute of Technology (MIT) will go to an expert in health measurement: Abraham Flaxman, an Assistant Professor of Global Health at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington (UW).

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Wockhardt receives final FDA approval for Felodipine ANDA to treat hypertension

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used in treating hypertension.

22 Aug 2012

AIDS Healthcare Foundation announces acquisition of MOMS Pharmacy

AIDS Healthcare Foundation (AHF), the largest nonprofit global HIV/AIDS organization, today announced that it has acquired MOMS Pharmacy, a specialty pharmacy focused exclusively on providing medications and support services to people living with HIV/AIDS.

21 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Researchers reveal possible drug targets to combat anthrax

A trawl of the genome of the deadly bacterium Bacillus anthracis has revealed a clutch of targets for new drugs to combat an epidemic of anthrax or a biological weapons attack.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Teva launches generic ACTOplus met to improve glucose control in adults with type 2 diabetes

Teva Pharmaceutical Industries Ltd. announced today the launch of an authorized generic of ACTOplus met (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg.

18 Aug 2012

Springer publishes Principles of Research Methodology: A Guide for Clinical Investigators

How do you teach medical research? How do you design a good study or develop a workable hypothesis? How do you shape research to improve patient care? These and many more questions are addressed in an authoritative textbook detailing the clinical research process, written by researchers and clinicians at SUNY Downstate Medical Center and other institutions.

17 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively.

16 Aug 2012

Biotechnology News and Research

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

NCKU research team identifies Au nanorod complex for cancer therapy

Proteonomix enters license agreement for new anti-tumor technology

New results describe development of DC cancer vaccine with enhanced immunogenic potential

NIH awards $100,000 STTR Phase I Grant to Transgenomic for pancreatic cancer research

SSEA4+ marker helps identify and isolate precursors of insulin-producing pancreatic cells

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Massachusetts Institute of Technology to honor IHME's health measurement expert

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

Wockhardt receives final FDA approval for Felodipine ANDA to treat hypertension

AIDS Healthcare Foundation announces acquisition of MOMS Pharmacy

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

Researchers reveal possible drug targets to combat anthrax

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Teva launches generic ACTOplus met to improve glucose control in adults with type 2 diabetes

Springer publishes Principles of Research Methodology: A Guide for Clinical Investigators

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News